[{"arm_notes": "", "treatment_id": null, "treatment_name": "This study is a multi-center; randomized; double-blind; placebo-controlled trial to assess the efficacy and safety of otilimab for the treatment of severe pulmonary COVID-19 related disease. The study population consists of hospitalized participants with new-onset hypoxia requiring significant oxygen support or requiring invasive mechanical ventilation (=48 hours before dosing). All participants will receive standard of care as per institutional protocols; in addition to study treatment. Participants will be randomized 1:1 by interactive response technology (IRT) in a blinded manner to receive either a blinded 1-hour infusion of otilimab 90 mg or placebo IV in addition to standard of care. Participants will be assessed daily until discharge (or Day 28; whichever is sooner); and followed up at Days 42 and 60 after randomization.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 940, "treatment_name": "Otilimab", "treatment_type": "Monoclonal antibodies", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]